Wockhardt gets US FDA nod for Cefprozil

Mumbai, June 20 (UNI) Pharmaceutical and biotechnology major Wockhardt has received the US FDA approval for its antibiotic Cefprozil tablets (250 mg and 500 mg).

Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections. Wockhardt will launch Cefprozil, the generic version of brand Cefzil, sold by Bristol Myers Squibb.

''Several of our products have seen a dramatic increase in market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around USD 51 million,'' Wockhardt chairman Habil Khorakiwala said in a statement here today.

UNI